abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb
Article

1 Oct 2004

Author:
Francis Weyzig, SOMO (Centre for research on Multinational Corporations)

[PDF] Sector profile of the pharmaceutical industry

[Report provides overview of pharmaceutical sector, examines issues such as: Access to medicines; clinical trials; drug safety; drug promotion & advertising; indigenous knowledge; workplace health, safety, environment; employment conditions.] [refers to Pfizer, Johnson & Johnson, Novartis, GlaxoSmithKline, Merck, Roche, AstraZeneca, Amgen, Eli Lilly, Aventis, DSM, Abbott Laboratories, Genentech, Sanofi-Synthélabo (part of Sanofi-Aventis), Wyeth, Bristol-Myers Squibb, Takeda Chemical, Forest Laboratories, Schering-Plough, Teva Pharmaceuticals, Bayer, Novo Nordisk (part of Novo Group), UCB (formerly Celltech), Mylan, Watson, Ranbaxy Laboratories, Boehringer Ingelheim, Cipla]